U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a bold plan to identify the cause of autism by September 2025. Speaking at a cabinet meeting with President Donald Trump, Kennedy declared a global research initiative involving hundreds of scientists to determine the source of rising autism rates, which reached 1 in 36 children by 2020, according to the CDC.
“We’ll know by September what has caused the autism epidemic and how to eliminate those exposures,” Kennedy said, hinting at environmental and artificial factors. The initiative is part of Trump’s broader “Make America Healthy Again” Commission, which is also reviewing rising childhood conditions like asthma and ADHD.
The autism community, however, responded with skepticism. Kristyn Roth of the Autism Society of America criticized the deadline and the framing of autism as an “epidemic,” warning it promotes fear and stigmatization. Experts caution that increased diagnoses are largely due to expanded diagnostic criteria and awareness, not an unknown epidemic.
Kennedy, known for promoting a disproven link between vaccines and autism, confirmed vaccines will be reviewed, along with potential environmental and lifestyle triggers. Meanwhile, a recent study has strengthened ties between prenatal diabetes and autism risk.
Controversy deepened after reports surfaced of David Geier—previously fined for unlicensed medical practices—being hired to investigate vaccine links. Lawmakers and advocacy groups fear the spread of misinformation under Kennedy’s leadership.
The National Institutes of Health and the CDC, both under Kennedy’s purview, are planning multimillion-dollar research efforts into autism causes, including vaccine-related studies. Critics argue the push may politicize science and mislead the public.
Despite widespread concern, Kennedy remains firm: “There will be no bigger news than finding the cause of autism.” Whether science can meet his deadline remains uncertain.


China Warns US Arms Sales to Taiwan Could Disrupt Trump’s Planned Visit
Neuralink Expands Brain Implant Trials with 12 Global Patients
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Trump Allegedly Sought Airport, Penn Station Renaming in Exchange for Hudson River Tunnel Funding
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 



